Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRW | ISIN: SE0015244520 | Ticker-Symbol: BIX0
München
05.09.25 | 08:02
2,675 Euro
-2,55 % -0,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,5552,64006.09.

Aktuelle News zur BIOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBioInvent International: BioInvent Announces Board of Directors Update402LUND, SE / ACCESS Newswire / September 2, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
26.08.BioInvent International AB: Interim Report January - June 2025204LUND, SE / ACCESS Newswire / August 26, 2025 / BioInvent International (STO:BINV) - "This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are...
► Artikel lesen
26.08.BioInvent International: BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation220Focusing on lead programs BI-1206 and BI-1808, with strong clinical data and upcoming value-creation milestonesPhase 2a study of BI-1206 in combination with pembrolizumab in first-line NSCLC to initiate...
► Artikel lesen
28.07.BioInvent International: Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 20252.121- Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInvent")...
► Artikel lesen
28.07.Transgene S.A.: Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 20254
12.06.BioInvent International: BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025373Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response:One complete response, three partial...
► Artikel lesen
11.06.BioInvent International: BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA in Solid Tumors451The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients...
► Artikel lesen
04.06.BioInvent International: BioInvent Presents at PAGE 2025 a Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Drug Candidate BI-1910321Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of dosesModel will support dose selection for upcoming studies; Phase 2a as...
► Artikel lesen
BIOINVENT Aktie jetzt für 0€ handeln
27.05.XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M2
27.05.XOMA Royalty Corporation; BioInvent: XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million2
14.05.BioInvent International: BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025474Data from the cutaneous T-cell lymphoma (CTCL) cohort demonstrate promising clinical activity that correlates with strong immune activationOne complete response (CR), three partial responses (PR), and...
► Artikel lesen
14.05.BioInvent International: BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma480Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response...
► Artikel lesen
05.05.BioInvent International: BioInvent to Participate in Upcoming Investor Conferences338LUND, SE / ACCESS Newswire / May 5, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
► Artikel lesen
05.05.BIOINVENT INTERNATIONAL AB: BioInvent secures FDA Fast Track Designation for BI-18082
29.04.BioInvent International: Resolutions at BioInvent's Annual General Meeting 2025336LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie...
► Artikel lesen
29.04.BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma817LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
29.04.BioInvent International AB: Interim Report January - March 2025380LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International (STO:BINV)"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic...
► Artikel lesen
09.04.BIOINVENT INTERNATIONAL AB: Takeda's milestone payment strengthens BioInvent's business model7
08.04.BioInvent International: BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3667LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
04.04.BioInvent International AB Publishes Annual Report 2024376LUND, SE / ACCESS Newswire / April 4, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
► Artikel lesen
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1